darunavir has been researched along with pyrimidinones in 33 studies
| Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (pyrimidinones) | Trials (pyrimidinones) | Recent Studies (post-2010) (pyrimidinones) |
|---|---|---|---|---|---|
| 1,148 | 224 | 780 | 6,059 | 604 | 2,692 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (66.67) | 29.6817 |
| 2010's | 11 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tachikawa, N | 1 |
| Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, PE | 1 |
| Banhegyi, D; Berger, D; de Béthune, MP; De Pauw, M; Lefebvre, E; Madruga, JV; McMurchie, M; Norris, D; Ruxrungtham, K; Spinosa-Guzman, S; Suter, F; Tomaka, F; Vangeneugden, T | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Bénard, A; Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Desbois, D; Descamps, D; Matheron, S; Peytavin, G; Roquebert, B | 1 |
| Andres, DA; Coffinier, C; Farber, EA; Fong, LG; Hrycyna, CA; Hudon, SE; Lee, R; Miner, JH; Nobumori, C; Spielmann, HP; Young, SG | 1 |
| Bacha, UM; Brower, ET; Freire, E; Kawasaki, Y | 1 |
| Andrade-Villanueva, J; De Meyer, S; De Pauw, M; Dejesus, E; Fourie, J; Khanlou, H; Lefebvre, E; Ortiz, R; Spinosa-Guzman, S; van Lunzen, J; Vangeneugden, T; Voronin, E | 1 |
| Louis, JM; Sayer, JM | 1 |
| Barrail-Tran, A; Chaix, ML; Delfraissy, JF; Ghosn, J; Pallier, C; Sahali, S | 1 |
| Estrada, V; Fuster, M | 1 |
| Curran, A; Ribera Pascuet, E | 1 |
| Antela López, A | 1 |
| García Deltoro, M | 1 |
| de Béthune, MP; De Meyer, S; De Paepe, E; DeMasi, R; Hill, A; Picchio, G | 1 |
| Angarano, G; Monno, L; Saracino, A; Tartaglia, A; Tinelli, C | 1 |
| de Béthune, MP; De Meyer, S; De Paepe, E; Dierynck, I; Lathouwers, E; Lefebvre, E; Picchio, G; Spinosa-Guzman, S; Van Baelen, B; Vangeneugden, T | 1 |
| Abeele, CV; Cassetti, I; Dierynck, I; Girard, PM; Jayaweera, D; Lavreys, L; Mills, AM; Nelson, M; Ruxrungtham, K; Sekar, V; Workman, C | 1 |
| Calvez, V; Hill, A; Marcelin, AG | 1 |
| Chandrasekar, S; Jayakanthan, M; Mathur, PP; Muthukumaran, J | 1 |
| Carper, MJ; Lei, X; Ramanadham, S; Richmond, SR; Yarasheski, KE; Zhang, S | 1 |
| Elder, JH; Lin, YC; Torbett, BE | 1 |
| Borland, J; Chen, S; Ishibashi, T; Lou, Y; Min, SS; Patel, P; Piscitelli, SC; Song, I | 1 |
| Chen, L; Demasi, R; Girard, PM; Lavreys, L; Nelson, M; Sekar, V; Smets, E | 1 |
| Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A | 1 |
| Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Allegri, G; Hemmett, L; Hjelmgren, J; Moeremans, K; Smets, E | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Lavreys, L; Picchio, G; Van de Casteele, T | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N | 1 |
4 review(s) available for darunavir and pyrimidinones
| Article | Year |
|---|---|
[Protease inhibitors].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides | 2005 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
[Safety and tolerability of darunavir].
Topics: Adult; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Lopinavir; Male; Multicenter Studies as Topic; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
[Resistance to darunavir].
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Lopinavir; Male; Multicenter Studies as Topic; Mutagenesis, Site-Directed; Mutation, Missense; Nitriles; Phenotype; Point Mutation; Pyridazines; Pyrimidines; Pyrimidinones; Randomized Controlled Trials as Topic; Sulfonamides | 2008 |
12 trial(s) available for darunavir and pyrimidinones
| Article | Year |
|---|---|
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides | 2007 |
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Weight Gain | 2008 |
[Darunavir in treatment-naïve patients. The ARTEMIS study].
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2008 |
[Darunavir as first-line therapy. The TITAN study].
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Darunavir; Diarrhea; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Prognosis; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lopinavir; Mutation; Protease Inhibitors; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Viral Load | 2009 |
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
Topics: Adult; Algorithms; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Logistic Models; Lopinavir; Male; Mutation; Pyrimidinones; Ritonavir; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Darunavir; Drug Combinations; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Sulfonamides; Young Adult | 2011 |
Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.
Topics: Adult; Anti-HIV Agents; Darunavir; HIV Infections; HIV-1; Humans; Lopinavir; Medication Adherence; Pyrimidinones; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mutation; Organophosphonates; Polymorphism, Genetic; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2011 |
17 other study(ies) available for darunavir and pyrimidinones
| Article | Year |
|---|---|
XVI International AIDS Conference: Part 2.
Topics: Acquired Immunodeficiency Syndrome; CCR5 Receptor Antagonists; Clinical Trials as Topic; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Ritonavir; Salvage Therapy; Sulfonamides | 2006 |
Darunavir phase 3 study data released.
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Pyrimidinones; Ritonavir; Sulfonamides | 2007 |
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Topics: Darunavir; HIV Protease; HIV Protease Inhibitors; HIV-2; Humans; Inhibitory Concentration 50; Lopinavir; Microbial Sensitivity Tests; Phenotype; Pyrimidinones; Saquinavir; Sulfonamides | 2008 |
A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
Topics: Animals; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Lamin Type A; Lipodystrophy; Lopinavir; Membrane Proteins; Metabolic Syndrome; Metalloendopeptidases; Mice; Mice, Knockout; Nuclear Proteins; Protein Precursors; Protein Processing, Post-Translational; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.
Topics: Darunavir; HIV Protease; HIV Protease Inhibitors; Hydrogen Bonding; Kinetics; Lopinavir; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Structure-Activity Relationship; Substrate Specificity; Sulfonamides | 2008 |
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
Switching to darunavir/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir/ritonavir.
Topics: Darunavir; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; Sulfonamides; Virus Replication | 2008 |
[Preserving future therapy options. Darunavir--the protease inhibitor for various patient groups].
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Clinical Trials as Topic; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Sulfonamides; Viral Load | 2008 |
Both a protective and a deleterious role for the L76V mutation.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Pyridines; Pyrimidinones; Pyrones; Sulfonamides | 2009 |
Prezista fares better than Kaletra in first line therapy.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pyrimidinones; Sulfonamides; Viral Load | 2009 |
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Computational Biology; Cytochrome P-450 CYP3A; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides | 2010 |
HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.
Topics: Animals; Atazanavir Sulfate; Carnitine O-Palmitoyltransferase; CD36 Antigens; Cell Line; Darunavir; Dose-Response Relationship, Drug; Fatty Acid Transport Proteins; Fatty Acids; HIV Protease Inhibitors; Humans; Lopinavir; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Oligopeptides; Oxidation-Reduction; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides | 2010 |
Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.
Topics: Amino Acid Substitution; Animals; Aspartic Acid Endopeptidases; Cats; Cell Line; Darunavir; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Immunodeficiency Virus, Feline; Inhibitory Concentration 50; Lopinavir; Pyrimidinones; Recombinant Proteins; Recombination, Genetic; Sulfonamides; Virus Replication | 2010 |
HIV-1 protease mutations and protease inhibitor cross-resistance.
Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides | 2010 |
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides | 2010 |
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Topics: Adult; Antiretroviral Therapy, Highly Active; Belgium; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Darunavir; Drug Resistance, Viral; Female; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Lopinavir; Male; Markov Chains; Multicenter Studies as Topic; Pyrimidinones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Sweden; United Kingdom; Viral Load | 2010 |
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2011 |